Support Systems and Multidisciplinary Treatment Approach
August 5th 2025Panelists discuss City of Hope’s multidisciplinary approach, highlighting pharmacists providing medication guidance, social workers offering emotional support, and palliative care specialists managing symptoms, while consultants like cardiologists and infectious disease experts address specific health issues to ensure coordinated, personalized care; complementary therapies such as acupuncture and mindfulness help manage side effects like neuropathy, and support groups foster community and resilience among patients and caregivers throughout their myeloma journey.
Watch
Patient Perspective: Adverse Events and Tolerability
August 5th 2025Panelists share that despite initial emotional challenges, multiple myeloma treatment with targeted combination therapies was generally well tolerated, with manageable side effects—especially after adjusting dexamethasone—and strong healthcare team support enabling patients to maintain quality of life and continue regular activities throughout therapy.
Watch
Adverse Event Management and Treatment Response Assessment
July 29th 2025Panelists discuss how patient portal use improves communication by allowing patients to report side effects with photos for accurate evaluation, and how treatment effectiveness is monitored through carefully timed blood tests, imaging, and bone marrow biopsies—including minimal residual disease testing—to balance thorough assessment with minimizing patient discomfort.
Watch
Patient Perspective: Navigating Multiple Myeloma Treatment
July 29th 2025Panelists discuss how patients newly diagnosed with multiple myeloma often face emotional and informational overload, but collaborative, personalized care—including early access to cutting-edge four-drug regimens, clear communication, and shared decision-making—can empower them, ease anxiety, and support long-term remission and quality of life.
Watch
Understanding Treatment Options for ER+/HER2–, ESR1-Mutant Metastatic Breast Cancer
July 24th 2025In this on-demand webinar series, Dr. Igor Makhlin discusses personalized treatment options for ER-positive, HER2-negative metastatic breast cancer, including the role of ESR1 mutation testing and targeted therapies like Orserdu.
Watch